MedTrace Logo

Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma

NCT05798897 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 79

Last updated 2025-08-20

No results posted yet for this study

Summary

This study is a Phase 1 multicenter study with a Dose Escalation and Dose Expansion evaluating safety and efficacy of MT-601 administration to patients with Relapsed or Refractory Lymphoma. The starting dose administered is 200 x 10\^6 cells (flat dosing).

Conditions

  • Non-Hodgkin Lymphoma, Adult
  • Non-Hodgkin Lymphoma, Refractory
  • Non-Hodgkin Lymphoma, Relapsed
  • Non Hodgkin Lymphoma
  • Hodgkin Lymphoma
  • Hodgkin Lymphoma, Adult
  • Hodgkin's Lymphoma, Relapsed, Adult

Interventions

DRUG

MT-601

Multi-antigen specific CD4+ andCD8+ T cells

Sponsors & Collaborators

  • Marker Therapeutics, Inc.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-02
Primary Completion
2028-02-28
Completion
2028-02-28
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05798897 on ClinicalTrials.gov